The benefits of haematopoietic growth factors in the management of gynaecological oncology

Neutropenia and anemia are important complications of cancer chemotherapy and can be prevented and treated with granulocyte colony-stimulating factor and erythropoietin.

Chemotherapy-related neutropenia; Chemotherapy-related anemia; Cancer and quality of life; Hematopoietic growth factors; Granulocyte colony-stimulating factor; Erythropoietin

[1] Hughes W. T., Armstrong D., Bodey G. P., Brown A. E., Edwards J. E., Feld R. et al.: "1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever". Clin. Infect. Dis., 1997, 25, 551.

[2] Chang J.: "Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer". Eur. J. Cancer, 1999, 36 suppl. 1, S11.

[3] Ozer H., Armitage J. O., Bennett C. L., Crawford J., Demetri G.D., Pizzo P. A. et al.: "Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines". J. Clin. Oneal., 2000, 18, 3558.

[4] ESMO: "ESMO recommendations for the application of haematopoietic growth factors (hGFs)". Ann. Oneal., 2001, 12, 1219.

[5] Dale D., Crawford J., Lyman G.: "Chemotherapy-induced neutropenia and associated complications in randomized clinical trials an evidence-based review". Proc. Am. Soc. Clin. Oneal., 2001, 20, 410a (Abstract 1638).

[6] Bodey G. P., Buckley M., Sathe Y. S., Freireich E. J.: "Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia". Ann. Intern. Med., 1966, 64, 328.

[7] Kuderer N. M., Cosler L., Crawford J., Dale D. C., Lyman G.: "Cost and mortality associated with febrile neutropenia in adult cancer patients". Proc. Am. Soc. Clin. Oneal., 2002, 21, 250a (Abstract 998)

[8] Trillet-Lenoir V., Green J., Manegold C., Von Pawel J., Gatzemeier U., Lebeau B. et al.: "Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy". Eur. J. Cancer, 1993, 29A, 319.

[9] Bonadonna G., Valagussa P.: "Dose-response effect of adjuvant chemotherapy in breast cancer". N. Eng. J. Med., 1981, 304, 10.

[10] Dale D. C., McCarter G., Crawford J., Lyman G. H.: "Delivered dose intensity in randomized clinical trials (RCTs) of chemotherapy in early-stage breast cancer (ESBC) and non-Hodgkin's lymphoma (NHL): a need for improved reporting". Proc. Am Soc. Clin. Oneal., 2002, 21, 252a (Abstract 1004).

[11] Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C.: "Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer". N. Eng. J. Med., 1995, 332, 901.

[12] Kaye S. B., Lewis C. R., Paul J., Duncan I. D., Gordon H. K., Kitchener H. C. et al.: "Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer". Lancet, 1992, 340, 329.

[13] Citron M., Berry D., Cirrinicione C., Carpenter J., Hudis C., Gradishar W. et al: "Superiority of dose-dense (DD) over conventional scheduling (CS) and equivalence of sequential (SC) vs. combination adjuvant chemotherapy (CC) for node-positive breast cancer (CALGB 9741, INT C9741)". Oral presentation at the 25'" Annual San Antonio Breast Cancer Symposium, December 11-13, 2002 (Abstract 15)

[14] Lyman G. H., Kuderer N. M., Agboola 0., Crawford J., Dale D. C.:'The epidemiology and economics of neutropenia in hospitalized cancer patients: data from the University HealthSystem Consortium". Blood, 2001, 98, 432a (Abstract 1813)

[15] Kuderer N. M., Crawford J., Dale D., Lyman G.: "Cost distributions and length of stay associated with febrile neutropenia in adult cancer patients". Supportive Care in Cancer, 2002, 10, 372 (Abstract P-71)

[16] Calhoun E. A., Welshman E. E., Change C-H., Lurain J. R., Bennett C. L.: "Cost of chemotherapy-induced neutropenia, thrombocytopenia and neurotoxicity". Proc. Am. Soc. Clin. Oncol., 2001, 20, 242a (Abstract 964).

[17] Erder M. H., Fridman M., Weaver C. H.: "Cancer patients (CPs ) perspectives about the impact of febrile neutropenia morbidity (FNM) on their well being (WB) and preferences for filgrastim treatment vs dose reduction to prevent FN: an internet survey" Proc. Am. Soc. Clin. Oneal., 2001, 20, 210b (Abstract 2589).

[18] Traynor B.: "Quality of life with filgrastim (r-metHuG-CSF)". In: "Filgrastim (r-metHuG-CSF) in Clinical Practice". Morstyn G., Dexter T. M. (eds). 1" edition. New York: Marcel Dekker, 1994, 319.

[19] Calhoun E. A., Chang C.-H., Welshman E. E., Cella D.: "Development and validation of the FACT-Neutropenia". Blood, 2001, 98, 427a (Abstract 1791).

[20] Calhoun E. A., Chang C.-H., Welshman E. E., Cella D.: "A neutropenia-specific quality of life instrument: rationale for the development of the FACT-N". Proc. Am. Soc. Clin. Oneal., 2002, 21, 375a (Abstract 1498)

[21] Pizzo P. A.: "Fever in immunocompromised patients". N. Engl. J. Med., 1999, 341, 893.

[22] Dale D.: "Management of febrile neutropenia: The shift from treatment to prevention". Oncol. Spectrums, 2002, 3, 6.

[23] Welte K. W., Gabrilove J., Bronchud M. H., Platzer E., Morstyn G.: "Filgrastim (r-metHuG-CSF): The first 10 years". Blood, 1996, 88, 1907.

[24] Heil G., Hoelzer D., Sanz M. A., Lechner K., Yin J. A. L., Papa G. et al.: "A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia". Blood, 1997, 90, 4710.

[25] Rivera E.,E rder M. H.,F ridman M.,B rannan C.,F rye D.,H ortobagyi G. N.: "Delivering full planned dose on time (PDOT) chemotherapy (CT) while lowering the incidence of febrile neutropenia (FN) hospitalizations: initial results form a prospective study (N=528) providing filgrastim support to high risk breast cancer patients (BCP)". Breast Cancer Res. Treat., 2001, 69, 209 (Abstract 3).

[26] De Graaf H., Willemse P. H. B., Bong S. B., Piersma H., Tjabbes T., van Veelen H. et al.: "Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer". Oncology, 1996, 53, 289

[27] Ribas A., Albanell J., Bellmunt J., Sole-Calvo L.-A., Bermejo B., Gallardo E. et al.: "Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy of breast cancer is a safe and cost-effective schedule to maintain dose-intensity". J. Clin. Oncol., 1996, 14, 1573.

[28] Lyman G. H., Kuderer N. M., Djulbegovic B.: "Prophylactic granulocyte colony-stimulating factor in patients receiving doseintensive cancer chemotherapy: a meta-analysis". Am. J. Med., 2002, 112, 406.

[29] Croockewit A. J., Bronchud M. H., Aapro M. S., Bargetzi M. J., Crown J., Gratwohl A. et al.: "A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC". Eur. J. Cancer, 1997, 33, 1732.

[30] Balducci L., Yates J.: "General guidelines for the management of older patients with cancer". Oncology, 2000, 14, 221.

[31] Lyman G. H., Kuderer N., Greene J., Balducci L.:'The economics of febrile neutropenia: implications for the use of colony-sti-mulating factors". Eur. J. Cancer, 1998, 34, 1857.

[32] Sivasubramaniam V.,D ale D.,C rawford J.,A gboola Y.,L yman G.: "Impact of outpatient treatment of febrile neutropenia (FN) on risk thresholds for G-CSF prophylaxis in cancer chemotherapy". Proc. Am. Soc. Clin. Oncol., 2001, 20, 392a. Abstract 1563

[33] Bennett C. L., Weeks J. A., Somerfield M. R., Feinglass J., Smith T. J.: "Use of hematopoietic colony-stimulating factors; comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines". J Clin. Oncol., 1999, 17, 3676.

[34] Balducci L., Hardy C. L., Lyman G. H.: "Hemopoietic reserve in the older cancer patient: clinical and economic considerations" Cancer Control, 2000, 7, 539.

[35] Silber J. H., Fridman M., DiPaola R. S., Erder M., Pauly M., Fox K.: "First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early-stage breast cancer therapy". J. Clin. Oncol., 1998, 16, 2392.

[36] Aslani A., Smith R., Allen B., Pavlakis N., Levi J.: "The predictive value of body protein for chemotherapy-induced toxicity" Cancer, 2000, 15, 796.

[37] Lininger L., Crawford J., Dale D., Chen H., Agboola Y., Stump E. et al.: "Predicting risk of neutropenic complications: a pointof-care assessment tool". Proc. Am. Soc. Clin. Oncol., 2001, 20, 411a (Abstract 1640).

[38] Lyman G. H., Crawford J., Dale D., Chen H., Agboola Y., Lininger L.: "Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy". Proc. Am. Soc. Clin. Oneal., 2001, 20, 394a (Abstract 1571)

[39] Dees E. C., O'Reilly S., Goodman S. N., Sartorius S., Levine M. A., Jones R. J. et al.: "A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer". Cancer Invest., 2000, 18, 521.

[40] Begg C. B., Elson P. J., Carbone P. P.: "A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols". In: "Cancer in the elderly; approaches to early detection and treatment". New York, Springer, 1989, 149.

[41] Chatta G. S., Price T. H., Stratton J. R., Dale D. C.: "Aging and marrow neutrophil reserves". J. Am. Geriatr. Soc., 1994, 42, 77.

[42] Bokemeyer C., Honecker F., Wedding U., Spath-Schwalbe E., Lipp H.P., Kolb G.: "Use ofhematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy". Onkologie，2002, 25, 32.

[43] Molineux G., Kinstler O., Briddell B., Hartley C., McElroy P., Kerzic P. et al.: "A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilise PBPC in both mice and humans". Exp. Hematol., 1999, 27, 1724.

[44] Holmes F. A., Jones S. E., O'Shaughnessy J., Yukelja S., George T., Savin M. et al.: "Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer". Ann. Oneal., 2002, 13, 903.

[45] Bedell C.: "Pegfilgrastim for chemotherapy-induced neutropenia". Clin. J. Oneal. Nurs., 2003, 7, 55.

[46] Holmes F. A., O'Shaughnessy J. A., Yukelja S., Jones S. E., Shogan J., Savin M. et al.: "Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer". J. Clin. Oneal., 2002, 20, 727.

[47] Green M. D., Koelbl H., Baselga J., Galid A., Guillem Y., Gascon P. et al.: "A randomized, double-blind, phase 3 study of fixeddose, single-administration pegfilgrastim vs daily filgrastim in patients receiving myelosuppressive chemotherapy". Ann. Oncol., 2003, 14, 29.

[48] Misset J. L., Dieras Y., Gruia G., Bourgeois H., Cvitkoic E., Kalla S. et al.: "Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer". Ann. Oneal., 1999, 10, 553.

[49] Siena S., Piccart M. J., Holmes F. A., Glaspy J., Hackett J., Renwick J.: "A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily fi lgrastim in patients with stage II-IV breast cancer". Oneal. Rep., 2003, 10, 715.

[50] Pettengell R.: "Advances in haematological support of cancer treatments". Eur. J. Hosp. Pharm., 2002, 2, 56.

[51] Groopman J. E., Itri L. M.: "Chemotherapy-induced anemia in adults; incidence and treatment". J. Natl. Cancer Inst., 1999, 91, 1616.

[52] Skillings J. R., Rogers-Melamed I., Nabholtz J.-M., Sawka G., Gwardry-Sridhar P., Moquin J.-P. et al.: "An epidemiological review of anaemia in cancer chemotherapy in Canada". Eur. J. Cancer, 1995, 31a (suppl. 5), S5 (Abstract 879)

[53] O'Shaughnessy J., Vukelja S., Savin M., Holmes F. A., Jones M., Royall D. et al.: "Effects of epoetin alfa (Procrit) on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy: a double-blind, randomised, placebo-controlled trial". Proc. Am. Soc. Clin. Oneal., 2002, 21, 363a (Abstract 1449).

[54] Demetri G. D., Gabrilove J. L., Blasi M. Y., Hill R. J., Glaspy J.: "Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy". Clin. Breast Cancer, 2002, 3, 45.

[55] Vogelzang N. J., Breitbart W., Cella D., Curt G. A., Groopman J. E., Horning S. J. et al.: "Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey". Semin. Hematol., 1997, 34 (suppl. 2), 4.

[56] Cella D.: "The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue". Semin. Hematol., 1997, 34 (suppl. 2),13.

[57] Caro J. J., Salas M., Ward A., Goss G.: "Anemia as an independent prognostic factor for survival in patient with cancer: a systematic, quantitative review". Cancer, 2001, 91, 2214.

[58] Frommhold H., Guttenberger R., Henke M.: "The impact of blood haemoglobin content on the outcome of radiotherapy. T he Freiburg experience". Strahlenther. Onkol., 1998, 174 (suppl. 4), 31.

[59] Littlewood T. J., Bajetta E., Nortier J. W., Vercammen E., Rapoport B.: "Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results or a randomised, double-blind, placebo-controlled trial". J. Clin. Oneal., 2001, 19, 2865.

[60] Lawless G., Royalty M. W., Meyers J.: "Epoetin practice pattern usage in community practice". Blood, 2000, 96, 390b (Abstract 5446).

[61] ISIS. Research conducted by ISIS Research Ltd. 2000. Data on file.

[62] Koeller J.: "Clinical guidelines for the treatment of cancer-related anaemia". Pharmacother, 1998, 18, 156.

[63] Demetri G. D.: "Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy". Br. J. Cancer, 2001, 84 (suppl. ]), 31.

[64] Elliott S. G., Lorenzini T., Strickland T., Delorme E., Egrie J. C.: "Rational design of novel erythropoiesis stimulating protein (Aranesp™): a super-sialyted molecule with increased biological activity". Blood, 2000, 96, 82a. Abstract 352.

[65] Egrie J. C., Browne J. K.: "Development and characterization of novel erythropoiesis stimulating protein (NESP)". Br. J. Cancer, 2001, 84 (suppl.1), 3.

[66] Heatherington A., Schuller J., Dittrich C., Mercer A. J., Rossi G.: "Intravenous (IV) administration of darbepoetin alfa to patients with nonmyeloid malignancies receiving multicycle chemotherapy; pharmacokinetic profiles". Proc. Am. Soc. Clin. Oncol., 2002, 21, 256b (Abstract 2844).

[67] Macdougall I. C., Gray S. J., Elston O., Breen C., Jenkins B., Browne J. et al.: "Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients". J. Am. Soc. Nephrol., 1999, 10, 2392.

[68] Glaspy J. A., Jadeja J. S., Justice G., Kessler J., Richards D., Schwartzberg L. et al.: "Darbepoetin alfa given every I or 2 weeks alleviates anaemia associated with cancer chemotherapy". Br. J. Cancer, 2002, 87, 268.

[69] Glaspy J. A., Tchekmedyian N. S.: "Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receivmg chemotherapy". Oncology, 2002, 16 (suppl. 11), 23.

[70] Hedenus M., Hansen S., Taylor K., Arthur C., Emmerich B., Dewey C. et al.: "Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies". Br. J. Haematol., 2002, 119, 79.

[71] Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M. et al.: "Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving cancer chemotherapy". J. Natl. Cancer Inst., 2002, 94, 1211.

[72] Kotasek D., Albertsson M., Mackey J., Berg R., Robinson J., Colowick A.: "Randomized, double-blind, placebo-controlled, dosefinding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumours". Proc. Am Soc. Clin. Oneal., 2002, 21, 356a (Abstract 1421).

[73] Smith R. E., Tchekmedyian S., Richards D., Klamet J., Fleishman A., Gayko U. et al.: "Darbepoetin alfa effectively alleviates anemia in patients with chronic anemia of cancer; efficacy and pharmacokinetic results of a doseescalation study". Proc. Am. Soc Clin. Oncol., 2002, 21, 367a (Abstract 1465).

[74] Kallich J., Erder H., Glaspy J., Vansteenkiste.T., Rossi G., Poulsen E. et al.: "Improvement in haemoglobin levels improves healthrelated quality of life (HRQOL) of anaemic cancer patients". Hematol. J., 2001, 1 (suppl. 1), 185 (Abstract 688).

[75] Glaspy J., Jadeha J., Justice G., Fleishman A., Armstrong S., Colowick A.: "Optimizing the management of anemia in cancer patients: a randomised, active-controlled, study investigating the dosing of darbepoetin alfa". Proc. Am. Soc. Clin. Oncol., 2002, 21, 362a (Abstract 1446).